Renaissance Capital

SPAC: BHAV Acquisition II lowers deal size by 33% ahead of $100 million IPO

BHAV Acquisition II, a blank check company targeting robotics, EVs, fintech, advanced computing and energy tech, lowered the ...
Renaissance Capital

Emerging markets fintech OPay sets terms for $320 million US IPO

OPay, a digital bank and fintech platform in Nigeria and other emerging markets, announced terms for its IPO on Friday.The ...
Renaissance Capital

Lycia Therapeutics prices upsized IPO at $18, the high end of the range

Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, raised $318 million ...
Renaissance Capital

Switzerland-based respiratory biotech Windward Bio Group files for a $100 million US IPO

Windward Bio Group, a Switzerland-based Phase 2/3 biotech developing antibodies for respiratory and dermatologic diseases, filed on Friday with the SEC to raise up to $100 million in an initial public ...
Renaissance Capital

US IPO Week Ahead: Africa-focused fintech target’s week sole IPO as Anthropic nears its public filing

One IPO is currently scheduled for the week ahead as investors continue to hold their breath for the year’s last potential mega IPO.Africa-focused digital bank and fintech platform OPay (OPAY) plans ...
Renaissance Capital

US IPO Weekly Recap: Trickle of biotech activity continues amid tech sell-off

One biotech IPO debuted this week, while four IPOs submitted initial filings, including two sizable biotech filings.Allergy and autoimmune biotech Lycia Therapeutics (LYCA) priced its upsized IPO at ...